Next, the selective impact of MKC‐8866 on IL‐7R signalling inhibition and concurrent activation of RAS led us to investigate the potential of targeting the RAS signalling pathway by applying the MEK inhibitor PD0325901 in combination with MKC‐8866 in our NRASG12D pre‐B ALL cells. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.